Dr. Falk Pharma PSC Trial Shows Positive Results
Dr. Falk Pharma announced positive 96-week results from its phase 3 NUC-5 trial of norucholic acid (NCA) for primary...
Arbutus Presents Promising HBV Data at EASL 2025
Arbutus Biopharma presented promising data at the EASL Congress 2025 for its chronic hepatitis B (cHBV) treatments, imdusiran and...
Bluejay Therapeutics Unveils Promising NASH Drug Data
Bluejay Therapeutics has revealed preclinical data on BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor designed to treat metabolic...
Clinuvel Recruits 200 Patients in Phase III Vitiligo Trial
Clinuvel Pharmaceuticals completed enrollment of over 200 patients in its Phase III trial (CUV105) for SCENESSE® (afamelanotide 16mg) as...
RapidPulse Stroke Study Begins Patient Enrollment
RapidPulse, Inc. has initiated patient enrollment in an Investigational Device Exemption (IDE) study for its cyclic aspiration system designed...
3-Year Safety and Efficacy of PCRX-201 in Knee Osteoarthritis
Pacira BioSciences announced Phase 1 data for its gene therapy candidate PCRX-201 (enekinragene inzadenovec) at the 2025 European Alliance...
Actuate Therapeutics Announces Topline Results From Phase 2 Elraglusib Trial
Actuate Therapeutics announced positive topline results from its Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for first-line...
Galimedix Phase 1 Dose Study of Oral Gal-101 Complete
Galimedix Therapeutics has completed the single ascending dose (SAD) portion of its Phase 1 study for oral GAL-101, a...
Understanding DPIAs in Clinical Research
Under the EU General Data Protection Regulation (GDPR), a Data Protection Impact Assessment (DPIA) is required when data processing...
Barzolvolimab Shows Promise in Eosinophilic Esophagitis Phase 2 Study
Celldex presented histology data from its Phase 2 trial of barzolvolimab for eosinophilic esophagitis (EoE) at the 2025 Digestive...